Cure My Disease

Don't miss your cure!

 Log in / Sign up

New targeted therapy shows promise for Tough-to-Treat ovarian cancer

NCT ID NCT04274426

Ongoing Disease control Sponsor: AGO Research GmbH Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called mirvetuximab soravtansine in people with a specific type of recurrent ovarian cancer that has high levels of a protein called folate receptor alpha. The drug delivers chemotherapy directly to cancer cells to try to slow or stop the cancer from growing. About 136 participants will be randomly assigned to receive either the new drug or standard platinum-based chemotherapy to see which works better.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT EPITHELIAL OVARIAN, FALLOPIAN OR PERITONEAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube carcinoma ovarian carcinoma peritoneal carcinomatosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT EPITHELIAL OVARIAN, FALLOPIAN OR PERITONEAL CARCINOMA

Contacts and locations

Locations

  • Charite - Universitätsmedizin Berlin

    Berlin, Germany

  • Evangelische Kliniken-Essen-Mitte

    Essen, Germany

  • Helios Klinikum Krefeld

    Krefeld, Germany

  • Klinikum Mannheim

    Mannheim, Germany

  • Klinikum Südstadt Rostock

    Rostock, Germany

  • LMU Klinikum

    München, Germany

  • Mammazentrum HH am Krankenhaus Jerusalem

    Hamburg, Germany

  • Medizinische Hochschule Hannover

    Hanover, Germany

  • OnkoNet Marburg GmbH

    Marburg, Germany

  • Rotkreuzklinikum München

    München, Germany

  • St. Elisabeth-Krankenhaus GmbH

    Köln-Hohenlind, Germany

  • Städtisches Klinikum Dessau

    Dessau, Germany

  • TU München, Klinikum recht der Isar

    München, Germany

  • Universitätsklinikum Carl-Gustav-Carus an der Technischen Universität Dresden

    Dresden, Germany

  • Universitätsklinikum Frankfurt

    Frankfurt, Germany

  • Universitätsklinikum Hamburg Eppendorf

    Hamburg, Germany

  • Universitätsklinikum Münster

    Münster, Germany

  • UniversitätsklinikumUlm

    Ulm, Germany

  • ViDia Christliche Kliniken Karlsruhe

    Karlsruhe, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.